ELI-002 7P / Elicio Therap - LARVOL DELTA

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. (PubMed, Nat Med) - P1 | "We present the final results of the phase 1 AMPLIFY-201 trial, in which patients who completed standard locoregional treatment, with minimal residual mKRAS disease (n = 25, 20 pancreatic cancer and 5 colorectal cancer), received monotherapy vaccination with lymph node-targeting ELI-002 2P, including mutant KRAS (mKRAS) amphiphile-peptide antigens (G12D, G12R) and amphiphile-adjuvant CpG-7909. Therefore, lymph node-targeting amphiphile vaccination induces persistent T cell responses targeting oncogenic driver KRAS mutations, alongside personalized, tumor antigen-specific T cells, which may correlate to clinical outcomes in pancreatic and colorectal cancer. ClinicalTrials.gov registration: NCT04853017 ."

IO biomarker • Journal • P1 data • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CD4 • CD8 • KRAS

Upcoming Anticipated Milestones for the AMPLIFY-7P Phase 2 Trial (GlobeNewswire) - "(i) Oral presentation in the Targeted Immunotherapies section at the World Vaccine Congress Washington 2026...highlighting the ELI-002 platform overview, updated Phase 1 2P data (safety, T-cell responses, correlations to tumor biomarkers, RFS and OS), Phase 1 7P data, and Phase 2 AMPLIFY-7P updates (T-cell responses, HLA association and antigen spreading); (ii) ELI-002 to be highlighted...at the American Association for Cancer Research ('AACR') Annual Meeting 2026...; (iii) Event-driven primary DFS analysis of the Phase 2 AMPLIFY-7P trial anticipated in 1H 2026; (iv) Plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration ('FDA') to finalize the Phase 3 trial design for ELI-002 7P in resected mKRAS PDAC following completion of the primary DFS analysis."

Clinical data • FDA event • Colorectal Cancer • Pancreatic Ductal Adenocarcinoma

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. (PubMed, Nat Med) - P1 | "Cancer vaccine ELI-002 2P enhances lymph node delivery and immune response using amphiphile (Amph) modification of G12D and G12R mutant KRAS (mKRAS) peptides (Amph-Peptides-2P) together with CpG oligonucleotide adjuvant (Amph-CpG-7909). ELI-002 2P was safe and induced considerable T cell responses in patients with immunotherapy-recalcitrant KRAS-mutated tumors. ClinicalTrials.gov identifier: NCT04853017 ."

IO biomarker • Journal • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CD4 • CD8 • KRAS

Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer (AACR 2024) - P1, P1/2 | "ELI-002 2P consists of 2 Amph-modified mKRAS peptide antigens, Amph-G12D and Amph-G12R (Amph-Peptides 2P), and an Amph-modified immune-stimulatory oligonucleotide adjuvant (Amph-CpG-7909). ELI-002 is an off-the-shelf vaccine targeting common KRAS tumor mutations demonstrating several key advantages: lymph node-targeted vaccine design, high immunogenicity, with balanced CD4+ and CD8+ T cell responses, HLA-agnostic activity, and targeting of vaccine antigens critical for tumor survival. A randomized Phase 2 clinical trial (NCT05726864) investigating a 7-peptide formulation (G12D, R, V, A, C, S, G13D) is underway."

IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor • CD4 • CD8 • GZMB • IFNG • IL2 • KRAS • TNFA

AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. (ASCO 2023) - P1, P1/2 | "In a 3+3 dose escalation, n=22 received a subcutaneous course of 6 prime and 4 booster injections of fixed dose Amph-peptides (1.4 mg), admixed with escalating Amph-CpG-7909 (Table). ELI-002 2P, evaluated in a novel MRD+ trial, was safe with ctDNA and serum tumor biomarker reduction and clearance and notable immune responses. The RP2D is the start dose for a phase 1/randomized phase 2 study evaluating a new seven peptide formulation for G12 D, R, V, S, A, C, and G13D mutated solid tumors (NCT05726864). Clinical trial information: NCT04853017."

Clinical • IO biomarker • P1 data • Colorectal Cancer • Fatigue • Gastrointestinal Cancer • Oncology • Pain • Pancreatic Cancer • Solid Tumor • CA 19-9 • CD4 • CD8 • KRAS • NRAS • RAS

First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors. (ASCO 2022) - P1 | "Patients with colon and pancreas cancer with Stage IV oligometastatic disease (< 3 lesions in one organ) rendered surgically free of disease and with MRD, are also eligible. The dose escalation portion of the study is currently enrolling."

IO biomarker • P1 data • Preclinical • Colorectal Cancer • Gallbladder Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor • KRAS • NRAS

Upcoming Anticipated Milestones for the Phase 2 AMPLIFY-7P Trial (Elicio Press Release) - "Upon reaching the event-driven primary DFS endpoint analysis, Elicio will request an End of Phase 2 meeting with the U.S. Food and Drug Administration ('FDA') to finalize the Phase 3 trial design for ELI-002 7P. Alignment on key elements of the Phase 3 study design was reached with the FDA at the End of Phase 1 meeting announced in Q1 2025."

FDA event • Colorectal Cancer • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (Elicio Press Release) - "The Company expects that its current cash and cash equivalents will support operations through Q2 2026, beyond the anticipated Phase 2 AMPLIFY-7P event-driven primary DFS endpoint analysis anticipated in 1H 2026."

Commercial • P2 data • Colorectal Cancer • Pancreatic Ductal Adenocarcinoma

AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma (SITC 2025) - "ELI-002 7P includes Amph-modified G12D, V, R, C, S, A and G13D mKRAS peptides with an Amph-modified immune-stimulatory oligonucleotide adjuvant (Amph-CpG-7909)...Prior ELI-002 2P Phase 1A results indicated initial safety, tolerability, and robust induction of mKRAS-specific T cell responses associated with improved disease-free survival (DFS) and overall survival (OS).1 2 The randomized Phase 2 trial is proceeding to final DFS analysis.Methods The ongoing randomized multicenter Phase 2 cohort was designed to assess the primary endpoint of DFS and immunogenicity as an exploratory endpoint...Local IRB approvals included: Memorial Sloan Kettering Cancer Center IRB (#22-352 and 22-352A(8)), Advarra (ID#s Pro00065733 and Pro00067455), the University of Iowa IRB (ID# 202212072), Feinstein Institutes for Medical Research, Northwell Health IRB (ID# 22-0814), University of California, Los Angeles Office of the Human Research Protection Program (ID# 22-001911), Mass General..."

Clinical • IO biomarker • Late-breaking abstract • P2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • CD4 • CD8 • IFNG • IL2 • KRAS • TNFA

Amphiphile (AMP)-Immunomodulator therapy controls growth and eradicates syngeneic solid tumors (SITC 2025) - P1, P1/2 | "Amphiphile (AMP)-CpG-7909 (ELI-004) is an ideal candidate in this context, as it has been designed to enhance tumor tissue retention by anchoring into cell membranes via its lipophilic AMP-tail.1 ELI-004 has been evaluated in multiple phase 1/2 trials (NCT04853017/NCT05726864) as part of an AMP-CpG-7909-adjuvanted peptide immunotherapy targeting mutant KRAS antigens (ELI-002). On day 42, ten days after the therapy phase concluded, tumor growth remained well controlled with 25% of mice achieving complete response and long-term non-progression, and no mice reaching euthanasia criteria. The 5 nmol AMP-CpG-7909 in situ treatment was well tolerated with no adverse safety observations.Conclusions Overall, these results demonstrate the potential for AMP-immunomodulators as promising off-the-shelf agents for in situ immunotherapy that is not patient-restricted or limited to specific tumor mutations and can induce potent cellular immune responses to control tumor growth."

Immunomodulating • IO biomarker • Oncology • Solid Tumor • KRAS

Title: AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma (GlobeNewswire) - "Elicio Therapeutics reports robust, cytolytic mKRAS-specific T cell responses across diverse patient HLA in ongoing phase 2 AMPLIFY-7P Trial of ELI-002 7P...at SITC....Among 90 evaluable patients treated with ELI-002 7P in the ongoing Phase 2 AMPLIFY-7P trial, 99% achieved robust mKRAS-specific T cell responses, with a mean145-fold increase over baseline. Consistent and broad immunogenicity was observed, with 85% of patients showing combined CD4 and CD8 T cell activation-previously correlated with clinical activity-and 86% of mKRAS target antigens (540/630) eliciting immune responses."

Late-breaking abstract • P2 data • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics to Present Clinical…Data at the SITC 2025 Annual Meeting (GlobeNewswire) - "Late-breaking poster presentation to highlight new immunogenicity data from ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancer."

Late-breaking abstract • P2 data • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial (Elicio Press Release) - "ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient population; Patients treated with ELI-002 7P represented a diverse HLA repertoire including 1,132 unique types identified among 1,398 total HLA backgrounds in assessed patients; 99% (88/89) of patients assessed for HLA background induced mKRAS-specific T cell responses after treatment with ELI-002 7P; Induction of mKRAS-specific T cell responses suggest that ELI-002 7P may address a broad patient population with high unmet need for pancreatic ductal adenocarcinoma ('PDAC')."

P2 data • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma (GlobeNewswire) - "The IIT will evaluate mFOLFIRINOX in combination with ELI-002 7P, with or without the anti–PD-1 antibody. The study is designed to enroll 20 patients across two cohorts (10 per arm). The trial is expected to commence in H1’2026."

New P1 trial • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial (GlobeNewswire) - "ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapy. Robust mKRAS-specific T cell responses were observed with an average of 145.3x increase over baseline (median 44.3x; range 2.13-1310x), consistent with prior ELI-002 Phase 1 trial results....Final disease-free survival analysis in the AMPLIFY-7P trial...is anticipated to occur in the fourth quarter of 2025."

P2 data • Colorectal Cancer • Pancreatic Ductal Adenocarcinoma

AMPLIFY-201: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: Elicio Therapeutics | Active, not recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Sep 2024

IO biomarker • Trial completion • Trial completion date • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gallbladder Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor • KRAS • NRAS

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients (GlobeNewswire) - "Direct ex vivo mKRAS-specific T cell responses were observed in 21/25 patients (84%), including both CD4+ and CD8+ T cell responses in 71% of patients, and 6/6 patients (100%) treated at the recommended Phase 2 dose ('RPD2'); the induction of both CD4+ and CD8+ T cells correlated with overall tumor biomarker response (p<0.0035)....At 19.7 months median follow-up (compared to 8.5 months previously), the median relapse-free survival ('RFS') was 16.33 months, and the median OS was 28.94 months for the 25-patient cohort."

P1 data • Colorectal Cancer • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (The Manila Times) - "Second Quarter 2025 Financial Results R&D expense for the second quarter of 2025 was $7.0 million, compared to $8.2 million for the second quarter of 2024. The decrease of $1.2 million was primarily due to less clinical trial manufacturing as we advanced ELI-002 7P clinical development...The Company expects that its current cash and cash equivalents will support operations into Q1 2026, beyond the anticipated AMPLIFY-7P Phase 2 final analysis."

Commercial • Colorectal Cancer • Neuroblastoma • Pancreatic Ductal Adenocarcinoma • Sarcoma

Elicio Therapeutics, Inc…announced that following the Independent Data Monitoring Committee’s (’IDMC’) pre-specified interim review of the unblinded safety and efficacy data in the Company’s Phase 2 AMPLIFY-7P study in mutant KRAS (’mKRAS’)-driven pancreatic ductal adenocarcinoma (GlobeNewswire) - "the IDMC recommended that the trial continue to the final analysis without modifications. In addition, the IDMC confirmed the favorable safety profile of ELI-002 7P to date...'We look forward to the final disease-free survival ('DFS') analysis anticipated to occur in the fourth quarter of 2025...we previously reached alignment with the U.S. Food and Drug Administration ('FDA') on the key elements of the planned pivotal Phase 3 study design, and, upon final DFS analysis, plan to request an End-of-Phase 2 meeting with the FDA to finalize the regulatory strategy for the ELI-002 Phase 3 study...The Company remains blinded to the trial clinical efficacy outcomes."

DSMB • P1/2 data • Pancreatic Ductal Adenocarcinoma

AMPLIFY-EAP: Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P=N/A | N=0 | Available | Sponsor: Elicio Therapeutics

IO biomarker • New trial • Neuroblastoma • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer (GlobeNewswire) - "Elicio Therapeutics...announced that it will host a virtual key opinion leader ('KOL') event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS ('mKRAS') driven pancreatic ductal adenocarcinoma ('PDAC'), one of the most lethal and underserved solid tumors....The discussion will also focus on Elicio’s lead product candidate, ELI-002, an AMP-powered therapeutic vaccine designed to overcome immune evasion. ELI-002 is currently being evaluated in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC, and an event-driven disease-free survival interim analysis of the study is anticipated in Q3 2025."

Clinical • P2 data • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Secures $10 Million in Financing (The Manila Times) - "The proceeds from the Note Financing, together with Elicio’s current cash and cash equivalents, are expected to support Elicio’s operations into the first quarter of 2026, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis expected in the third quarter of 2025."

Commercial • P2 data • Colorectal Cancer • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) - "Upcoming Anticipated Milestones: (i) DFS event-driven interim analysis of Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025; (ii) Potential to finalize pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in H2 2025."

New P3 trial • P2 data • Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy (GlobeNewswire) - "Elicio Therapeutics, Inc...today announced that it has received supportive feedback in an End of Phase 1 Type B meeting with the U.S. Food and Drug Administration ('FDA') regarding the registrational strategy for ELI-002. Based on the feedback received, Elicio would expect to file a Biologics License Application ('BLA') if supported by a planned Phase 3 trial."

FDA event • Pancreatic Cancer

AMPLIFY-7P: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (clinicaltrials.gov) - P1/2 | N=158 | Active, not recruiting | Sponsor: Elicio Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • IO biomarker • CNS Tumor • Colorectal Cancer • Neuroblastoma • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Sarcoma • Solid Tumor • KRAS • NRAS